---
document_datetime: 2025-12-02 05:04:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-viatris.html
document_name: cinacalcet-viatris.html
version: success
processing_time: 0.1322854
conversion_datetime: 2025-12-28 05:05:16.925187
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cinacalcet Viatris (previously Cinacalcet Mylan)

[RSS](/en/individual-human-medicine.xml/65624)

##### Authorised

This medicine is authorised for use in the European Union

cinacalcet Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cinacalcet Viatris (previously Cinacalcet Mylan)](#news-on)
- [More information on Cinacalcet Mylan](#more-information-on-cinacalcet-mylan-1028)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Cinacalcet Viatris is a medicine used to:

- treat secondary hyperparathyroidism (overactive parathyroid glands) in adults with serious kidney disease who need dialysis (to clear their blood of waste products);
- reduce hypercalcaemia (high blood calcium levels) in adults with cancer of the parathyroid glands or with primary hyperparathyroidism when the parathyroid glands cannot be removed.

In hyperparathyroidism, the parathyroid glands in the neck produce too much parathyroid hormone (PTH), which can lead to high levels of blood calcium, bone and joint pain and deformities of the arms and legs. 'Secondary' means that it is caused by another condition (serious kidney disease) while 'primary' means there is no other cause.

Cinacalcet Viatris contains the active substance cinacalcet and is a 'generic medicine'. This means that Cinacalcet Viatris is similar to a 'reference medicine' already authorised in the European Union (EU). The reference medicine for Cinacalcet Viatris is Mimpara.

For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Cinacalcet Viatris used?

Cinacalcet Viatris is available as tablets, to be taken with food or shortly after a meal.

In patients with secondary hyperparathyroidism, the medicine is taken once a day and the dose is adjusted according to the patient's PTH and calcium levels.

In patients with hypercalcaemia who also have parathyroid gland cancer or primary hyperparathyroidism, the medicine is taken twice a day. The dose is increased and taken up to 3 or 4 times a day as necessary to reduce blood calcium to normal levels.

The medicine can only be obtained with a prescription.

For more information about using Cinacalcet Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Cinacalcet Viatris work?

The active substance in Cinacalcet Viatris, cinacalcet, is a calcimimetic agent. This means that it mimics the action of calcium in the body. Cinacalcet works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands that regulate PTH secretion. By increasing the sensitivity of these receptors, cinacalcet leads to a reduction in the production of PTH by the parathyroid glands. The reduction in PTH levels leads to a decrease in blood calcium levels.

## How has Cinacalcet Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Mimpara, and do not need to be repeated for Cinacalcet Viatris.

As for every medicine, the company provided studies on the quality of Cinacalcet Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Cinacalcet Viatris?

Because Cinacalcet Viatris is a generic medicine and is bioequivalent to the reference medicine, Mimpara, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Cinacalcet Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Cinacalcet Viatris has been shown to have comparable quality and to be bioequivalent to Mimpara. Therefore, the Agency's view was that, as for Mimpara, the benefits outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Cinacalcet Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cinacalcet Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Mimpara also apply to Cinacalcet Viatris where appropriate.

As for all medicines, data on the use of Cinacalcet Viatris are continuously monitored. Suspected side effects reported with Cinacalcet Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Cinacalcet Viatris

Cinacalcet Mylan received a marketing authorisation valid throughout the EU on 19 November 2015.

The name of the medicine was changed to Cinacalcet Viatris on 15 October 2024.

Cinacalcet Mylan : EPAR - Medicine overview

Reference Number: EMA/536273/2024

English (EN) (165.55 KB - PDF)

**First published:** 27/11/2015

**Last updated:** 27/01/2025

[View](/en/documents/overview/cinacalcet-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-216)

български (BG) (189.01 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/bg/documents/overview/cinacalcet-mylan-epar-medicine-overview_bg.pdf)

español (ES) (165.07 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/es/documents/overview/cinacalcet-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (187.33 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/cs/documents/overview/cinacalcet-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (164.14 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/da/documents/overview/cinacalcet-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (169.32 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/de/documents/overview/cinacalcet-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (163.3 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/et/documents/overview/cinacalcet-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (189.44 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/el/documents/overview/cinacalcet-mylan-epar-medicine-overview_el.pdf)

français (FR) (166.4 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/fr/documents/overview/cinacalcet-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (184.93 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/hr/documents/overview/cinacalcet-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (163.81 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/it/documents/overview/cinacalcet-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (196.77 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/lv/documents/overview/cinacalcet-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (187.18 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/lt/documents/overview/cinacalcet-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (186.16 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/hu/documents/overview/cinacalcet-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (189.96 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/mt/documents/overview/cinacalcet-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (165.43 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/nl/documents/overview/cinacalcet-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (191 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/pl/documents/overview/cinacalcet-mylan-epar-medicine-overview_pl.pdf)

português (PT) (166.03 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/pt/documents/overview/cinacalcet-mylan-epar-medicine-overview_pt.pdf)

română (RO) (139.79 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/ro/documents/overview/cinacalcet-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (187.16 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/sk/documents/overview/cinacalcet-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (184.44 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/sl/documents/overview/cinacalcet-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (163.31 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/fi/documents/overview/cinacalcet-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (163.77 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/01/2025

[View](/sv/documents/overview/cinacalcet-mylan-epar-medicine-overview_sv.pdf)

Cinacalcet Mylan : EPAR - Risk-management-plan summary

English (EN) (48.71 KB - PDF)

**First published:** 27/11/2015

**Last updated:** 27/11/2015

[View](/en/documents/rmp-summary/cinacalcet-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Cinacalcet Viatris : EPAR - Product Information

English (EN) (306.26 KB - PDF)

**First published:** 27/11/2015

**Last updated:** 07/10/2025

[View](/en/documents/product-information/cinacalcet-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-412)

български (BG) (613.45 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/bg/documents/product-information/cinacalcet-viatris-epar-product-information_bg.pdf)

español (ES) (428.65 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/es/documents/product-information/cinacalcet-viatris-epar-product-information_es.pdf)

čeština (CS) (432.55 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/cs/documents/product-information/cinacalcet-viatris-epar-product-information_cs.pdf)

dansk (DA) (553.32 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/da/documents/product-information/cinacalcet-viatris-epar-product-information_da.pdf)

Deutsch (DE) (522.05 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/de/documents/product-information/cinacalcet-viatris-epar-product-information_de.pdf)

eesti keel (ET) (221.31 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/et/documents/product-information/cinacalcet-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (375.67 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/el/documents/product-information/cinacalcet-viatris-epar-product-information_el.pdf)

français (FR) (472.28 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/fr/documents/product-information/cinacalcet-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (581.69 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/hr/documents/product-information/cinacalcet-viatris-epar-product-information_hr.pdf)

íslenska (IS) (532.65 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/is/documents/product-information/cinacalcet-viatris-epar-product-information_is.pdf)

italiano (IT) (342.18 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/it/documents/product-information/cinacalcet-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (303.42 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/lv/documents/product-information/cinacalcet-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (413.87 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/lt/documents/product-information/cinacalcet-viatris-epar-product-information_lt.pdf)

magyar (HU) (237.18 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/hu/documents/product-information/cinacalcet-viatris-epar-product-information_hu.pdf)

Malti (MT) (759.16 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/mt/documents/product-information/cinacalcet-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (338.26 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/nl/documents/product-information/cinacalcet-viatris-epar-product-information_nl.pdf)

norsk (NO) (354.61 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/no/documents/product-information/cinacalcet-viatris-epar-product-information_no.pdf)

polski (PL) (463.35 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/pl/documents/product-information/cinacalcet-viatris-epar-product-information_pl.pdf)

português (PT) (226.45 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/pt/documents/product-information/cinacalcet-viatris-epar-product-information_pt.pdf)

română (RO) (558.7 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/ro/documents/product-information/cinacalcet-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (591.84 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/sk/documents/product-information/cinacalcet-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (415.59 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/sl/documents/product-information/cinacalcet-viatris-epar-product-information_sl.pdf)

Suomi (FI) (338.48 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/fi/documents/product-information/cinacalcet-viatris-epar-product-information_fi.pdf)

svenska (SV) (488.61 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

07/10/2025

[View](/sv/documents/product-information/cinacalcet-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000302017 07/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cinacalcet Viatris : EPAR - All authorised presentations

English (EN) (40.38 KB - PDF)

**First published:** 27/11/2015

**Last updated:** 17/10/2024

[View](/en/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-375)

български (BG) (81.27 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/bg/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (64.1 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/es/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (91.37 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/cs/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (94.04 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/da/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.4 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/de/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (53.77 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/et/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (70.39 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/el/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (75.99 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/fr/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (112.1 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/hr/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (93.71 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/is/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (35.74 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/it/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.19 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/lv/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.09 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/lt/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (39.78 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/hu/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.15 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/mt/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (53.29 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/nl/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.29 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/no/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.2 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/pl/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.84 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/pt/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (56.79 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/ro/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.59 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/sk/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.28 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/sl/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (94.81 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/fi/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.95 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

17/10/2024

[View](/sv/documents/all-authorised-presentations/cinacalcet-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cinacalcet Viatris (previously Cinacalcet Mylan) Active substance cinacalcet hydrochloride International non-proprietary name (INN) or common name cinacalcet Therapeutic area (MeSH)

- Hyperparathyroidism, Secondary
- Hypercalcemia

Anatomical therapeutic chemical (ATC) code H05BX01

### Pharmacotherapeutic group

Calcium homeostasis

### Therapeutic indication

Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.

Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate.

Reduction of hypercalcaemia in patients with:

- parathyroid carcinoma
- primary HPT for whom parathyroidectomy

would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

## Authorisation details

EMA product number EMEA/H/C/004014

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park

Opinion adopted 24/09/2015 Marketing authorisation issued 19/11/2015 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cinacalcet Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.6 KB - PDF)

**First published:** 07/10/2025

[View](/en/documents/procedural-steps-after/cinacalcet-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cinacalcet Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (707.24 KB - PDF)

**First published:** 10/02/2017

**Last updated:** 07/10/2025

[View](/en/documents/procedural-steps-after/cinacalcet-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Cinacalcet Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/695643/2015

English (EN) (2.84 MB - PDF)

**First published:** 27/11/2015

**Last updated:** 27/11/2015

[View](/en/documents/assessment-report/cinacalcet-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cinacalcet Mylan

Adopted

Reference Number: EMA/CHMP/596066/2015

English (EN) (74.18 KB - PDF)

**First published:** 25/09/2015

**Last updated:** 25/09/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cinacalcet-mylan_en.pdf)

#### News on Cinacalcet Viatris (previously Cinacalcet Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-september-2015) 25/09/2015

#### More information on Cinacalcet Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/10/2025

## Share this page

[Back to top](#main-content)